{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:26:42Z","timestamp":1784320002844,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":257,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["182704"],"award-info":[{"award-number":["182704"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority.","doi-asserted-by":"publisher","award":["39905"],"award-info":[{"award-number":["39905"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["182704"],"award-info":[{"award-number":["182704"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with metastatic colorectal cancer receiving palliative chemotherapy have a 5-year survival rate of approximately 10 per cent. Liver transplantation using strict selection criteria in patients with colorectal cancer and unresectable liver-only disease will result in a 5-year survival rate of 56\u201383 per cent. The aim of this study was to evaluate survival of patients with colorectal liver metastases (CRLM) after liver transplantation using extended criteria for both patients and donors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a prospective single-arm study. Patients with synchronous unresectable CRLM who were not suitable for arms A, B or C of the SEcondary CAncer (SECA) II study who had undergone radical resection of the primary tumour and received chemotherapy were included; they underwent liver transplantation with extended criteria donor grafts. Patients who had resectable pulmonary metastases were eligible for inclusion. The main exclusion criteria were BMI above 30 kg\/m2 and liver metastases larger than 10 cm. Survival was estimated using Kaplan\u2013Meier analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten patients (median age 54 years; 3 women) were included. They had an extensive liver tumour load with a median of 20 (range 1\u201345) lesions; the median size of the largest lesion was 59 (range 15\u201394)\u00a0mm. Eight patients had (y)pN2 disease, six had poorly differentiated or signet ring cell-differentiated primary tumours, and five had primary tumour in the ascending colon. The median Fong clinical risk score was 3 (range 2\u20135) and the median Oslo score was 1 (range 1\u20134). The median plasma carcinoembryonic antigen level was 4\u00b73 (range 2\u20134346)\u00a0\u03bcg\/l. Median disease-free and overall survival was 4 and 18 months respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with unresectable liver-only CRLM undergoing liver transplantation with extended patient and donor criteria have relatively short overall survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs5.50278","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T08:59:28Z","timestamp":1587805168000},"page":"467-477","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study)"],"prefix":"10.1093","volume":"4","author":[{"given":"T M","family":"Smedman","sequence":"first","affiliation":[{"name":"Department of Oncology , Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P-D","family":"Line","sequence":"additional","affiliation":[{"name":"Department of Transplantation Medicine , Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hagness","sequence":"additional","affiliation":[{"name":"Department of Transplantation Medicine , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Syversveen","sequence":"additional","affiliation":[{"name":"Radiology and Nuclear Medicine , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9271-8789","authenticated-orcid":false,"given":"H","family":"Grut","sequence":"additional","affiliation":[{"name":"Radiology and Nuclear Medicine , Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6125-6689","authenticated-orcid":false,"given":"S","family":"Dueland","sequence":"additional","affiliation":[{"name":"Department of Oncology , Oslo, Norway"},{"name":"Experimental Transplantation and Malignancy Research Group, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"2022100812275817100_bjs550278-bib-0001","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"2022100812275817100_bjs550278-bib-0002","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/SLA.0b013e3181fcf3e3","article-title":"Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?","volume":"252","author":"Adam","year":"2010","journal-title":"Ann Surg"},{"key":"2022100812275817100_bjs550278-bib-0003","first-page":"283","article-title":"Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors","volume":"4","author":"Kanas","year":"2012","journal-title":"Clin Epidemiol"},{"key":"2022100812275817100_bjs550278-bib-0004","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1245\/s10434-015-4370-1","article-title":"Recurrence after partial hepatectomy for metastatic colorectal cancer: potentially curative role of salvage repeat resection","volume":"22","author":"Butte","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2022100812275817100_bjs550278-bib-0005","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","article-title":"Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy","volume":"27","author":"Kopetz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022100812275817100_bjs550278-bib-0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jnci\/djq456","article-title":"Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis","volume":"103","author":"Masi","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2022100812275817100_bjs550278-bib-0007","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/SLA.0b013e31828ee17c","article-title":"Liver transplantation for neuroendocrine tumors in Europe \u2013 results and trends in patient selection: a 213-case European Liver Transplant Registry study","volume":"257","author":"Le Treut","year":"2013","journal-title":"Ann Surg"},{"key":"2022100812275817100_bjs550278-bib-0008","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"2022100812275817100_bjs550278-bib-0009","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cld.2011.08.004","article-title":"Transplantation for cholangiocarcinoma","volume":"15","author":"Masuoka","year":"2011","journal-title":"Clin Liver Dis"},{"key":"2022100812275817100_bjs550278-bib-0010","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","article-title":"Liver transplantation for nonresectable liver metastases from colorectal cancer","volume":"257","author":"Hagness","year":"2013","journal-title":"Ann Surg"},{"key":"2022100812275817100_bjs550278-bib-0011","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/SLA.0000000000003404","article-title":"Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases","volume":"271","author":"Dueland","year":"2020","journal-title":"Ann Surg"},{"key":"2022100812275817100_bjs550278-bib-0012","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/lt.24791","article-title":"Compagnons H\u00e9pato-Biliaires Group. Liver transplantation for colorectal liver metastasis: survival without recurrence can be achieved","volume":"23","author":"Toso","year":"2017","journal-title":"Liver Transpl"},{"key":"2022100812275817100_bjs550278-bib-0013","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hep.27283","article-title":"Excess mortality on the liver transplant waiting list: unintended policy consequences and model for end-stage liver disease (MELD) inflation","volume":"61","author":"Northup","year":"2015","journal-title":"Hepatology"},{"key":"2022100812275817100_bjs550278-bib-0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.yasu.2012.03.005","article-title":"What is the prognosis after retransplantation of the liver?","volume":"46","author":"Zarrinpar","year":"2012","journal-title":"Adv Surg"},{"key":"2022100812275817100_bjs550278-bib-0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"2022100812275817100_bjs550278-bib-0016","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00259-017-3843-9","article-title":"The prognostic value of 18F-FDG PET\/CT prior to liver transplantation for nonresectable colorectal liver metastases","volume":"45","author":"Grut","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2022100812275817100_bjs550278-bib-0017","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"2022100812275817100_bjs550278-bib-0018","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/bjs.10769","article-title":"Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma","volume":"105","author":"Dueland","year":"2018","journal-title":"Br J Surg"},{"key":"2022100812275817100_bjs550278-bib-0019","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2022100812275817100_bjs550278-bib-0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/MNM.0000000000000843","article-title":"Importance of 18F-FDG PET\/CT to select patients with nonresectable colorectal liver metastases for liver transplantation","volume":"39","author":"Grut","year":"2018","journal-title":"Nucl Med Commun"},{"key":"2022100812275817100_bjs550278-bib-0021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/bjs.10651","article-title":"Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases","volume":"105","author":"Grut","year":"2018","journal-title":"Br J Surg"},{"key":"2022100812275817100_bjs550278-bib-0022","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1245\/s10434-017-6264-x","article-title":"The impact of primary tumor location on long-term survival in patients undergoing hepatic resection for metastatic colon cancer","volume":"25","author":"Creasy","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2022100812275817100_bjs550278-bib-0023","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1245\/s10434-016-5361-6","article-title":"Prognostic implication of KRAS status after hepatectomy for colorectal liver metastases varies according to primary colorectal tumor location","volume":"23","author":"Sasaki","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2022100812275817100_bjs550278-bib-0024","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ejso.2018.02.210","article-title":"The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis","volume":"44","author":"Wang","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"2022100812275817100_bjs550278-bib-0025","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/annonc\/mdy140","article-title":"Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO","volume":"29","author":"Cremolini","year":"2018","journal-title":"Ann Oncol"},{"key":"2022100812275817100_bjs550278-bib-0026","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/SLA.0000000000002968","article-title":"Is hepatectomy justified for BRAF mutant colorectal liver metastases?: A multi-institutional analysis of 1497 patients","volume":"271","author":"Gagni\u00e8re","year":"2020","journal-title":"Ann Surg"},{"key":"2022100812275817100_bjs550278-bib-0027","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","article-title":"Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study","volume":"30","author":"Tveit","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022100812275817100_bjs550278-bib-0028","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41416-018-0115-9","article-title":"Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome","volume":"118","author":"Thomsen","year":"2018","journal-title":"Br J Cancer"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs5.50278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bjs5.50278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bjs5.50278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/4\/3\/467\/46350918\/bjs550278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/4\/3\/467\/46350918\/bjs550278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T12:40:15Z","timestamp":1665232815000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/4\/3\/467\/6061460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5,29]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs5.50278","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"2019-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}